Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Achilles Therapeutics plc (ACHL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.6000-0.0950 (-3.53%)
At close: 04:00PM EDT
2.6700 +0.07 (+2.69%)
After hours: 04:34PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • J
    James
    Next clinical data will be presented at SITC.
  • J
    James
    This year there will be interim data from ten patients, first patient will dosed in the combo trials, they will enrol the first patient in the US, an IND will be filed for HNSCC, and Catapult manufacturing will come on-line.
  • J
    James
    The company has dosed the first patient with higher-dose cNeT (CHIRON) and initiated enrollment in Cohort B of THETIS.
  • p
    pjtrader
    I have read the report a few times and still cant really understand why the market isn't liking it...
  • A
    Aaron
    Nice, surprising action today.
  • E
    Erik
    They made a point in saying their potency tests might be better than IOVA's in their call. Though long IOVA, if so, they may have some decent runway.
  • A
    Aaron
    Good news. Markets up. High volume. And we are still down....what gives?
  • J
    James
    The primary objective of this trial is to assess the safety and tolerability of cNeT as monotherapy and in combination with pembrolizumab, and also evaluate the clinical efficacy as a secondary measure. Additional data evaluating cNeT persistence, phenotype, and functionality will be reviewed while also exploring potential biomarkers of clinical activity and factors affecting response. This will include analysis of patient samples using a bespoke plasma ctDNA assay.''With 75% of patients with NSCLC presenting with inoperable or metastatic disease and a 5-year survival for stage IV disease as low #$%$, additional treatments are needed for this large patient population including autologous cell therapies like Achilles? cNeT,'' commented Dr. Jamal-Hanjani. ''The rationale of the trial is very evident as we know that NSCLC patients with tumours that have a high burden of clonal neoantigens have improved disease free survival and increased sensitivity to checkpoint inhibition.''''Just as with our melanoma trial, this allows us to look at the safety and tolerability of our precision cNeT as monotherapy and in combination with a checkpoint inhibitor,'' said Dr. Peggs, CMO of Achilles. ''While the primary purpose of the trials is safety, the addition of these checkpoint combination cohorts will allow further examination of T cell kinetics and the contribution of cell dose and checkpoint therapy to treatment outcomes. Further, we will continue to look at the predictive value of ctDNA as a potential marker for clinical events as we look towards the future of our product with potential companion diagnostics in addition to our planned potency assays.''https://ir.achillestx.com/static-files/645c95d7-bdbe-438a-9ca2-98b57e680123
  • p
    pjtrader
    Now they are saying its a buy with a 27 dollar target...go figure :-)
    Bullish
  • J
    James
    The company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second half of 2024, including full funding of the ongoing Phase I/IIa CHIRON and THETIS trials.
  • J
    James
    The company shared initial data from its Material Acquisition Platform, highlighting the ability of its proprietary VELOS manufacturing process to extract personalised cell therapy candidates across several solid tumour types.

    Disclosed as part of a presentation at the ESGCT Congress, the data read included 74 patient samples that were processed at the time of submission. In line with publicly available data, its PELEUS platform has identified 107 clonal neoantigens in NSCLC samples, 156 in melanoma samples, and 71 in head and neck squamous cell carcinoma samples. The collection of patient material is currently underway across eight sites in the U.K., EU, and the U.S.
  • C
    Chari
    Very small float. Being played.
  • m
    ming
    It is a good undervalued stock, but the market value is too small, and it is controlled by the short side.
  • J
    James
    Interim analysis on ten patients across the two trials is expected in Q4, the first PD-1 combination trial (in melanoma) should start then, and so should the higher median doses* to recruitment.

    * With VELOS Process one (used now), T-cells and harvested from the tumour and DCs are loaded with clonal peptides, activate and this drives cNet expansion. For Process two, additional cytokines (undisclosed) boost the harvest of tumour reactive T-cells and an optimised DC-driven co-culture followed by short T-cell boost increases the final cNeT dose.
  • C
    Chari
    @James, Is this a good entry point?
  • N
    Nabil
    Errrr What’s going on here??
  • K
    KB
    they will pop some great news to boost price soon.
    Bullish
  • J
    James
    The company has presented positive data at ESMO I-O Congress on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens. There was an over 10-fold dose increase at GMP scale with VELOS Process two manufacturing. In addition, cNeT maintain CD4+ and CD8+ T-cell subsets with a highly potent polyclonal phenotype. Dosing of patients is expected in 1H 2022.
  • J
    James
    In a case study from the ongoing THETIS trial, a patient diagnosed with melanoma received a three cycle combination of Yervoy and Opdivo which was stopped due to toxicity. Last year, they had a recurrent lesion excised and cNeT manufactured through the VELOS process. The specificity and fitness of the cNeT were measured by flow cytometric analysis of IFN-y and TNF-a cytokines, markers of T-cell activity. Up to 53% of the T-cells in the manufactured product were reactive to the patient's own clonal neoantigens following stimulation. The cNeT can be tracked after dosing by using peptides that incorporate patient-specific clonal mutations from the tumour to stimulate cells from the blood of the patient. By using ELISpot technology to detect cNeT that produce cytokine in response to this stimulus, the expansion and persistence of cNeT in circulation can be calculated https://ir.achillestx.com/static-files/eefe8e60-023f-4beb-9681-44e4451032bc
Advertisement
Advertisement